You are here

Article Text

Article menu
Download PDFPDF
Commentary
Prevention of endpoints in primary biliary cholangitis with ursodeoxycholic acid: quantifying the benefit

https://doi.org/10.1136/gutjnl-2019-320355

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Twitter @schattenbergj

    • Contributors This is my sole work.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests JMS has acted as consultant to Intercept Pharmaceuticals, Genfit, Gilead Sciences, Novartis, Echosens, Pfizer, Roche and Siemens Healthineers and has received Research Funding from Gilead Sciences.

    • Patient consent for publication Not required.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles